BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

RNAC upcoming catalysts

Cartesian Therapeutics: 2 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 1 readout(s) and 0 FDA event(s). Subscribe to RNAC (.ics).

Drugs: Descartes-08, Decartes-08

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-01 est.P2Cartesian Therapeutics RNACNCT06038474 Descartes-08 for Patients With Systemic Lupus ErythematosusSystemic Lupus Erythematosus (SLE)active not recruiting6
2026-12-30 est.P3Cartesian Therapeutics RNACNCT06799247 Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisMyasthaenia Gravisactive not recruiting128

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-01-05P2Cartesian Therapeutics RNACNCT04146051 Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)Myasthenia Gravis, Generalizedactive not recruiting30

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.